Anna Palmer
Overview
Explore the profile of Anna Palmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
342
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmer A, Sharma S, Nagpal J, Kimani V, Mai F, Ahmed Z
JMIR Form Res
. 2024 Aug;
8:e56000.
PMID: 39133910
Background: The NHS (National Health Service) COVID-19 app was a digital contact tracing app (DCTA) used in England in response to the COVID-19 pandemic. The aim of which was to...
2.
Win T, Draper B, Palmer A, Htay H, Sein Y, Shilton S, et al.
JGH Open
. 2023 Nov;
7(11):755-764.
PMID: 38034058
Background And Aim: The availability of direct-acting antiviral (DAA) treatment and point-of-care diagnostic testing has made hepatitis C (HCV) elimination possible even in low- and middle-income countries (LMICs); however, testing...
3.
Houdroge F, Palmer A, Delport D, Walsh T, Kelly S, Hainsworth S, et al.
Sci Rep
. 2023 Jan;
13(1):1398.
PMID: 36697434
Between June and August 2020, an agent-based model was used to project rates of COVID-19 infection incidence and cases diagnosed as positive from 15 September to 31 October 2020 for...
4.
Houdroge F, Yunus H, Delport D, Stearns E, Palmer A, Naim A, et al.
BMJ Glob Health
. 2022 Oct;
7(10).
PMID: 36220307
Introduction: With limited resources, attaining maximal average health service coverage can be at odds with maximising equity which attempts to promote greater reach among underserved populations. In this study, we...
5.
Kerr C, Stuart R, Mistry D, Abeysuriya R, Rosenfeld K, Hart G, et al.
PLoS Comput Biol
. 2021 Jul;
17(7):e1009149.
PMID: 34310589
The COVID-19 pandemic has created an urgent need for models that can project epidemic trends, explore intervention scenarios, and estimate resource needs. Here we describe the methodology of Covasim (COVID-19...
6.
Palmer A, Papaluca T, Stoove M, Winter R, Pedrana A, Hellard M, et al.
Int J Drug Policy
. 2021 Mar;
94:103203.
PMID: 33744667
Background: Hepatitis C is highly prevalent among prisoners. The simplicity of direct-acting antiviral (DAA) treatment for hepatitis C makes it possible to use novel models of care to increase treatment...
7.
Modelling the impact of relaxing COVID-19 control measures during a period of low viral transmission
Scott N, Palmer A, Delport D, Abeysuriya R, Stuart R, Kerr C, et al.
Med J Aust
. 2020 Nov;
214(2):79-83.
PMID: 33207390
Objectives: To assess the risks associated with relaxing coronavirus disease 2019 (COVID-19)-related physical distancing restrictions and lockdown policies during a period of low viral transmission. Design: Network-based viral transmission risks...
8.
Palmer A, Higgs P, Scott N, Agius P, Maher L, Dietze P
Addiction
. 2020 Aug;
116(4):876-888.
PMID: 32770761
Aims: To estimate the prevalence of and risk factors associated with concurrent injection of multiple substances (co-injection) among a community-recruited cohort of people who inject drugs. Design: Cross-sectional study. Setting:...
9.
Palmer A, Scott N, Dietze P, Higgs P
Harm Reduct J
. 2020 Feb;
17(1):14.
PMID: 32106854
Aims: We report on motivations for crystal methamphetamine-opioid co-use/co-injection through narratives of people who inject drugs during a period of increased crystal methamphetamine use reporting in Australia. Methods: Fourteen in-depth...
10.
Boulton A, Kells N, Cogger N, Johnson C, OConnor C, Webster J, et al.
Prev Vet Med
. 2019 Nov;
174:104836.
PMID: 31765960
The objective of this study was to identify risk factors for morbidity and mortality of bobby calves across the whole dairy supply chain in New Zealand. A case-control study was...